Your browser doesn't support javascript.
loading
Treatment effects of soluble guanylate cyclase modulation on diabetic kidney disease at single-cell resolution.
Balzer, Michael S; Pavkovic, Mira; Frederick, Julia; Abedini, Amin; Freyberger, Alexius; Vienenkötter, Julia; Mathar, Ilka; Siudak, Krystyna; Eitner, Frank; Sandner, Peter; Grundmann, Manuel; Susztak, Katalin.
Affiliation
  • Balzer MS; Renal, Electrolyte, and Hypertension Division, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Institute for Diabetes, Obesity and Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Departmen
  • Pavkovic M; Bayer AG, Research and Early Development, Pharma Research Center, 42096 Wuppertal, Germany.
  • Frederick J; Renal, Electrolyte, and Hypertension Division, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Institute for Diabetes, Obesity and Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Abedini A; Renal, Electrolyte, and Hypertension Division, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Institute for Diabetes, Obesity and Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Freyberger A; Bayer AG, Research and Early Development, Pharma Research Center, 42096 Wuppertal, Germany.
  • Vienenkötter J; Bayer AG, Research and Early Development, Pharma Research Center, 42096 Wuppertal, Germany.
  • Mathar I; Bayer AG, Research and Early Development, Pharma Research Center, 42096 Wuppertal, Germany.
  • Siudak K; Bayer AG, Research and Early Development, Pharma Research Center, 42096 Wuppertal, Germany.
  • Eitner F; Bayer AG, Research and Early Development, Pharma Research Center, 42096 Wuppertal, Germany; Division of Nephrology and Clinical Immunology, RWTH Aachen University, 52062 Aachen, Germany.
  • Sandner P; Bayer AG, Research and Early Development, Pharma Research Center, 42096 Wuppertal, Germany; Department of Pharmacology, Hannover Medical School, 30625 Hannover, Germany.
  • Grundmann M; Bayer AG, Research and Early Development, Pharma Research Center, 42096 Wuppertal, Germany.
  • Susztak K; Renal, Electrolyte, and Hypertension Division, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Institute for Diabetes, Obesity and Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Departmen
Cell Rep Med ; 4(4): 100992, 2023 04 18.
Article in En | MEDLINE | ID: mdl-37023747
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus / Diabetic Nephropathies Type of study: Risk_factors_studies Limits: Animals / Humans Language: En Journal: Cell Rep Med Year: 2023 Document type: Article Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus / Diabetic Nephropathies Type of study: Risk_factors_studies Limits: Animals / Humans Language: En Journal: Cell Rep Med Year: 2023 Document type: Article Country of publication: United States